Skip To Main Content
Helen Albert on Muck Rack

Helen Albert

Verified
Berlin, Germany
As seen in: Inside Precision Medicine, Forbes, Nature, New Scientist, Taylor & Francis Online, Chemical & Engineering News (C&EN), Forbes Brasil, Genetic Engineering & Biotechnology News, Forbes Japan, Chemistry World, Labiotech and
Covers:  Life sciences, technology, medicine, health, general science, biotech/pharma, innovation
Freelance journalist. Focus: med, life sci, bioanth & biotech. Bylines: Forbes, BMJ, New Scientist, Chemistry World, Labiotech & more. Senior ed. @Inside_PM

Get in touch with Helen

Contact Helen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Helen Albert’s Biography

Read Full Bio →

Helen is a freelance science and health journalist based in Berlin. She has written for a range of publications including Forbes New Scientist and the BMJ. Prior to going freelance in 2020, she was Editor-in-Chief at Labiotech.eu, an English-language, digital publication based in Berlin focusing on the European biotech industry. Before moving to Germany, she worked at a range of different science and health-focused publications in London. She was Editor of The Biochemist magazine and blog, but …

Articles

ProMIS’s Alzheimer’s Antibody Achieves Encouraging Early Results

|
By Helen Albert Verified
| Inside Precision Medicine Verified
Credit: Naeblys/Getty Images ProMIS Neurosciences reports positive six-month interim results from a Phase Ib trial of its antibody therapy targeting toxic amyloid‑beta oligomers in patients with early stage Alzheimer’s disease.
Open in Who Shared Issue with article?

MapLight’s Schizophrenia Candidate Has Mixed Results at Phase II

|
By Helen Albert Verified
| Inside Precision Medicine Verified
Credit: Iuliia Isaieva/Getty Images MapLight Therapeutics announced this week that its candidate drug for treatment of schizophrenia had achieved its primary endpoint in a Phase II trial, but only at the twice daily dose tested in the trial. As reported by the California-based company, while participants of the trial who were given the candidate drug, ML-007C-MA, once a day did show some signs of improvement it was not statistically significant.
Open in Who Shared Issue with article?

Gut Bacteria Chemical Linked to Irregular Heart Beat

|
By Helen Albert Verified
| Inside Precision Medicine Verified
Credit: wildpixel/Getty Images A chemical called trimethylamine N-oxide (TMAO), which originates from gut bacteria digesting animal products such as red meat, is present at higher levels in the blood of people with an irregular heart beat than the rest of the population.
Open in Who Shared Issue with article?
See all 1,378 licensed articles (1,388 Total)

Interview

What was your first job as a journalist?

working as a writer at medwireNews in London

How do you prefer to be pitched on stories?

By email

What's your favorite social network?

Twitter or LinkedIn